Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01128855 · ClinicalTrials.gov registry record · Phase 1
A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01128855 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 20 participants.
The verdict
NCT01128855, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is investigate the pharmacokinetics, safety and tolerability of single subcutaneous administration of GSK2402968 in non-ambulant boys with Duchenne muscular dystrophy
Interventions
- OTHER Placebo
- DRUG 3 mg/kg GSK2402968
- DRUG 6 mg/kg GSK2402968
- DRUG 9 mg/kg GSK2402968
- DRUG 12 mg/kg GSK2402968
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-07-12 |
| Est. Completion | 2011-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01128855
The ClinicalTrials.gov registry entry for NCT01128855 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01128855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01128855 about?
NCT01128855 is a clinical study titled "A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects". The purpose of this study is investigate the pharmacokinetics, safety and tolerability of single subcutaneous administration of GSK2402968 in non-ambulant boys with Duchenne muscular dystrophy
What is the current status of trial NCT01128855?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-07-12. Estimated completion is 2011-10-25.
What interventions are being tested in trial NCT01128855?
The interventions under investigation include: Placebo (OTHER), 3 mg/kg GSK2402968 (DRUG), 6 mg/kg GSK2402968 (DRUG), 9 mg/kg GSK2402968 (DRUG), 12 mg/kg GSK2402968 (DRUG).
Who is sponsoring clinical trial NCT01128855?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.